High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages 504-508

  Ulisse, Salvatore ^a   Baldini, Enke ^a   Sorrenti, Salvatore ^a   Barollo, Susi ^b   Gnessi, Lucio ^a   Catania, Antonio ^a   Pellizzo, Maria Rosa ^c   Nardi, Francesco ^a   Mian, Caterina ^c   De Antoni, Enrico ^a   D'Armiento, Massimino ^a   Frati, Luigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RADIOACTIVE IODINE; THYROID HORMONE; UROKINASE; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; GENE EXPRESSION; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CHILD; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 79951712621     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1688     Document Type: Article

References (20)

1. Ulisse S, Baldini E, Sorrenti S, D'Armiento M 2009 The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9:32-71
2. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG 2000 The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60:636-643 (Pubitemid 30094561)
3. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein M, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens J 2002 Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 Breast Cancer Patients. J Natl Cancer Inst 94:116-128 (Pubitemid 34121291)
4. Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group 2001 randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913-920
5. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC, American Society of Clinical Oncology 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312 (Pubitemid 350232263)
6. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511 (Pubitemid 36173719)
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer Statistics, 2009. Ca Cancer J Clin 59:225-249
8. Nikiforv YE, Biddinger PW, Thompson LDR, eds. 2009 Diagnostic pathology and molecular genetics of the thyroid. Philadelphia: Lippincott Williams, Wilkins
9. Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A, D'Armiento M 2006 Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective studi of 500 cases diagnosed over 20 years. Thyroid 16:1151-1155 (Pubitemid 44864490)
10. Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch 2001 Prognostic factors in cancer. 2nd ed. International Union Against Cancer. New York: Wiley-Liss
11. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW 2006 Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91:313-319 (Pubitemid 43069155)
12. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762 (Pubitemid 350294294)
13. Handkiewicz-Junak D, Czarniecka A, Jarzab B 2010 Molecular prognostic markers in papillary thyroid cancer: current status and future directions. Mol Cell Endocrinol 322:8-28
14. Shibru D, Chung KW, Kebebew E 2008 Recent developments in the clinical application of thyroid cancer biomarkers. Curr Opin Oncol 20:13-18 (Pubitemid 350190976)
15. Ulisse S, Baldini E, Toller M, Marchioni E, Giacomelli L, De Antoni E, Ferretti E, Marzullo A, Graziano FM, Trimboli P, Biordi L, Curcio F, Gulino A, Ambesi-Impiombato FS, D'Armiento M 2006 Differential expression of the components of the plasminogen activating system in human thyroid tumor derived cell lines and papillary carcinomas. Eur J Cancer 42:2631-2638 (Pubitemid 44468383)
16. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65:1587-1597 (Pubitemid 40270189)
17. Horvatiç Herceg G, Herceg D, Kralik M, Bence-Zigman Z, Tomiç-Brzac H, Kuliç A 2006 Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien Klin Wochenschr 118:601-609
18. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H 2009 Urokinase receptor,MMP-1andMMP- 9are marker to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 125: 894-901
19. Hedinger C, Williams ED, Sobin LH 1989 The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63:908-911 (Pubitemid 19063200)
20. Pfaffl MW, Vandesompele J, Kubista M 2009 Data analysis software (2009) in real-time PCR: current technology and applications. Logan J, Edwards K, Saunders N, eds. London: Applied and Functional Genomics, Health Protection Agency, Caister Academic Press